Evidence map›Paper›PMID 33251553›Full record

ReviewJournal of ophthalmic inflammation and infection2020

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN

Bahram Bodaghi, Quan Dong Nguyen, Glenn Jaffe, Ramin Khoramnia, Carlos Pavesio

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of ophthalmic inflammation and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023
    Article
  13. Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023
    Review
  14. Sarcoidosis-Related Uveitis: A Review.Journal of clinical medicine · 2023
    Review
  15. Article
  16. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Article
  17. Intravitreal Fluocinolone Acetonide Implant (ILUVIENDrug design, development and therapy · 2023
    Review
  18. Article
  19. [Bilateral vasculitis following intravitreal brolucizumab injection].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Bahram BodaghiDepartment of Ophthalmology, IHU FOReSIGHT, Sorbonne-APHP, Paris, France.
Quan Dong NguyenByers Eye Institute, Spencer Center for Vision Research, Stanford University of Medicine, Palo Alto, California, USA.
Glenn JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina, USA.
Ramin KhoramniaInternational Vision Correction Research Centre (IVCRC), The David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany.
Carlos PavesioMoorfields Eye Hospital, London, UK. carlos.pavesio@moorfields.nhs.uk.
Assistance Publique – Hôpitaux de Paris · FRDuke University · USHeidelberg University · DEStanford University · USUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, 'Preventing relapse of non-infectious uveitis effecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant.' MAIN TEXT: The fluocinolone acetonide intravitreal implant was approved in Europe for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye and offers a systemic therapy-sparing treatment option by providing low daily dose of corticosteroid into the vitreous for up to 3 years. In the symposium, the presenters reported clinical outcomes from patients with non-infectious uveitis effecting the posterior segment of the eye to support the effectiveness and safety of the implant for up to 3 years in both randomised controlled trials and real-world practices.

conclusionsData showed that over a 36 month period, treatment with the fluocinolone acetonide intravitreal implant was associated with significantly fewer episodes of uveitic recurrence, a significantly longer time to uveitic recurrence, greater improvement in visual acuity, a lower need for adjunctive therapy, and an acceptable safety profile.

Indexed as

ChronicCorticosteroidFluocinolone acetonideImplantIntravitrealMacular oedemaMicrodosingNon-infectious uveitisPosterior segment of eyeRecurrence

Identifiers

PMID33251553
PMCPMC7701203
OpenAlexW3108978639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.